PDF(Pubmed)
Abstract：
BACKGROUND: Our current understanding of how computerized brain training drives cognitive and functional benefits remains incomplete. This paper describes the protocol for Improving Neurological Health in Aging via Neuroplasticity-based Computerized Exercise (INHANCE), a randomized controlled trial in healthy older adults designed to evaluate whether brain training improves cholinergic signaling.
OBJECTIVE: INHANCE evaluates whether 2 computerized training programs alter acetylcholine binding using the vesicular acetylcholine transporter ligand [18F] fluoroethoxybenzovesamicol ([18F] FEOBV) and positron emission tomography (PET).
METHODS: In this phase IIb, prospective, double-blind, parallel-arm, active-controlled randomized trial, a minimum of 92 community-dwelling healthy adults aged 65 years and older are randomly assigned to a brain training program designed using the principles of neuroplasticity (BrainHQ by Posit Science) or to an active control program of computer games designed for entertainment (eg, Solitaire). Both programs consist of 30-minute sessions, 7 times per week for 10 weeks (35 total hours), completed remotely at home using either loaned or personal devices. The primary outcome is the change in FEOBV binding in the anterior cingulate cortex, assessed at baseline and posttest. Exploratory cognitive and behavioral outcomes sensitive to acetylcholine are evaluated before, immediately after, and 3 months following the intervention to assess the maintenance of observed effects.
RESULTS: The trial was funded in September 2019. The study received approval from the Western Institutional Review Board in October 2020 with Research Ethics Board of McGill University Health Centre and Health Canada approvals in June 2021. The trial is currently ongoing. The first participant was enrolled in July 2021, enrollment closed when 93 participants were randomized in December 2023, and the trial will conclude in June 2024. The study team will be unblinded to conduct analyses after the final participant exits the study. We expect to publish the results in the fourth quarter of 2024.
CONCLUSIONS: There remains a critical need to identify effective and scalable nonpharmaceutical interventions to enhance cognition in older adults. This trial contributes to our understanding of brain training by providing a potential neurochemical explanation of cognitive benefit.
BACKGROUND: ClinicalTrials.gov NCT04149457; https://clinicaltrials.gov/ct2/show/NCT04149457.
UNASSIGNED: DERR1-10.2196/59705.
OBJECTIVE: INHANCE evaluates whether 2 computerized training programs alter acetylcholine binding using the vesicular acetylcholine transporter ligand [18F] fluoroethoxybenzovesamicol ([18F] FEOBV) and positron emission tomography (PET).
METHODS: In this phase IIb, prospective, double-blind, parallel-arm, active-controlled randomized trial, a minimum of 92 community-dwelling healthy adults aged 65 years and older are randomly assigned to a brain training program designed using the principles of neuroplasticity (BrainHQ by Posit Science) or to an active control program of computer games designed for entertainment (eg, Solitaire). Both programs consist of 30-minute sessions, 7 times per week for 10 weeks (35 total hours), completed remotely at home using either loaned or personal devices. The primary outcome is the change in FEOBV binding in the anterior cingulate cortex, assessed at baseline and posttest. Exploratory cognitive and behavioral outcomes sensitive to acetylcholine are evaluated before, immediately after, and 3 months following the intervention to assess the maintenance of observed effects.
RESULTS: The trial was funded in September 2019. The study received approval from the Western Institutional Review Board in October 2020 with Research Ethics Board of McGill University Health Centre and Health Canada approvals in June 2021. The trial is currently ongoing. The first participant was enrolled in July 2021, enrollment closed when 93 participants were randomized in December 2023, and the trial will conclude in June 2024. The study team will be unblinded to conduct analyses after the final participant exits the study. We expect to publish the results in the fourth quarter of 2024.
CONCLUSIONS: There remains a critical need to identify effective and scalable nonpharmaceutical interventions to enhance cognition in older adults. This trial contributes to our understanding of brain training by providing a potential neurochemical explanation of cognitive benefit.
BACKGROUND: ClinicalTrials.gov NCT04149457; https://clinicaltrials.gov/ct2/show/NCT04149457.
UNASSIGNED: DERR1-10.2196/59705.
摘要：
背景：我们目前对计算机化大脑训练如何驱动认知和功能益处的理解仍然不完整。本文介绍了通过基于神经可塑性的计算机运动（INHANCE）改善衰老中的神经健康的协议，一项针对健康老年人的随机对照试验,旨在评估大脑训练是否能改善胆碱能信号传导.
目的：INHANCE使用囊泡型乙酰胆碱转运体配体[18F]氟乙氧基苯并韦维考（[18F]FEOBV）和正电子发射断层扫描（PET）评估两种计算机化训练计划是否改变了乙酰胆碱结合。
方法：在此阶段IIb，prospective,双盲,平行臂,主动对照随机试验，至少92名65岁及以上的社区居住健康成年人被随机分配到使用神经可塑性原理设计的大脑训练计划(BrainHQbyPositScience)或为娱乐设计的电脑游戏的主动控制程序(例如，接龙)。这两个节目包括30分钟的会议，每周7次，共10周（共35小时），使用借来的或个人设备在家中远程完成。主要结果是前扣带皮质FEOBV结合的变化，在基线和后验时评估。在评估对乙酰胆碱敏感的探索性认知和行为结果之前，紧接着,和干预后3个月，以评估观察到的效果的维持。
结果：该试验于2019年9月获得资助。该研究于2020年10月获得西方机构审查委员会的批准，麦吉尔大学健康中心研究伦理委员会于2021年6月获得加拿大卫生部的批准。目前正在进行审判。第一位参与者于2021年7月注册，当2023年12月随机分配93名参与者时，注册结束，该试验将于2024年6月结束。研究小组将在最终参与者退出研究后进行分析。我们预计将于2024年第四季度公布业绩。
结论：仍然迫切需要确定有效和可扩展的非药物干预措施来增强老年人的认知功能。该试验通过提供认知益处的潜在神经化学解释，有助于我们对大脑训练的理解。
背景：ClinicalTrials.govNCT04149457;https://clinicaltrials.gov/ct2/show/NCT04149457。
■DERR1-10.2196/59705。
目的：INHANCE使用囊泡型乙酰胆碱转运体配体[18F]氟乙氧基苯并韦维考（[18F]FEOBV）和正电子发射断层扫描（PET）评估两种计算机化训练计划是否改变了乙酰胆碱结合。
方法：在此阶段IIb，prospective,双盲,平行臂,主动对照随机试验，至少92名65岁及以上的社区居住健康成年人被随机分配到使用神经可塑性原理设计的大脑训练计划(BrainHQbyPositScience)或为娱乐设计的电脑游戏的主动控制程序(例如，接龙)。这两个节目包括30分钟的会议，每周7次，共10周（共35小时），使用借来的或个人设备在家中远程完成。主要结果是前扣带皮质FEOBV结合的变化，在基线和后验时评估。在评估对乙酰胆碱敏感的探索性认知和行为结果之前，紧接着,和干预后3个月，以评估观察到的效果的维持。
结果：该试验于2019年9月获得资助。该研究于2020年10月获得西方机构审查委员会的批准，麦吉尔大学健康中心研究伦理委员会于2021年6月获得加拿大卫生部的批准。目前正在进行审判。第一位参与者于2021年7月注册，当2023年12月随机分配93名参与者时，注册结束，该试验将于2024年6月结束。研究小组将在最终参与者退出研究后进行分析。我们预计将于2024年第四季度公布业绩。
结论：仍然迫切需要确定有效和可扩展的非药物干预措施来增强老年人的认知功能。该试验通过提供认知益处的潜在神经化学解释，有助于我们对大脑训练的理解。
背景：ClinicalTrials.govNCT04149457;https://clinicaltrials.gov/ct2/show/NCT04149457。
■DERR1-10.2196/59705。
